Does DABRAFENIB Cause Second primary malignancy? 125 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 125 reports of Second primary malignancy have been filed in association with DABRAFENIB (Tafinlar). This represents 0.7% of all adverse event reports for DABRAFENIB.
125
Reports of Second primary malignancy with DABRAFENIB
0.7%
of all DABRAFENIB reports
27
Deaths
40
Hospitalizations
How Dangerous Is Second primary malignancy From DABRAFENIB?
Of the 125 reports, 27 (21.6%) resulted in death, 40 (32.0%) required hospitalization, and 6 (4.8%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DABRAFENIB. However, 125 reports have been filed with the FAERS database.
What Other Side Effects Does DABRAFENIB Cause?
Pyrexia (3,788)
Death (2,740)
Malignant neoplasm progression (1,667)
Fatigue (1,328)
Nausea (1,300)
Chills (1,235)
Rash (1,078)
Vomiting (907)
Diarrhoea (901)
Headache (697)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which DABRAFENIB Alternatives Have Lower Second primary malignancy Risk?
DABRAFENIB vs DABRAFENIB\TRAMETINIB
DABRAFENIB vs DACARBAZINE
DABRAFENIB vs DACLATASVIR
DABRAFENIB vs DACLIZUMAB
DABRAFENIB vs DACOMITINIB